Archive
534 articles, sorted by publication time.
The focus of this clinical data is not only more accurate glucose readings, but whether continuous glucose monitoring can identify false hypoglycemia caused by pressure during sleep, bringing alarms closer to the physiological changes that truly need attention.
A seemingly technical drug-control lawsuit is pulling cannabis policy back to more fundamental questions: who should guide the next step in the regulatory system: scientific assessment, public health, or entrenched industry interests?
Both companies stand in prominent positions in new biopharmaceutical technologies, but behind the investment narrative lie very different scientific risks, funding pressures, and paths to clinical validation.
Immune checkpoint inhibitors can give a small number of cancer patients long-term benefit, but they also leave many people facing ineffective treatment and side effects. A new model from a Harvard team refocuses attention on the molecular interactions between tumors and the immune system, but prospective validation is still needed before it can become a clinical decision-making tool.
The first AI-assisted vaccine candidate has entered clinical testing, pushing vaccine development on the front lines of outbreaks one step further in imagination; but from assembling an antigen by algorithm to proving it can protect populations, there remains a long road of safety, immune response, and regulatory review.
From small molecules and antibodies to nucleic acid medicines, the pharmaceutical industry is reallocating its therapeutic toolbox; the new agreement between CSPC Pharmaceutical Group and AstraZeneca reflects how siRNA therapies are moving from rare diseases toward broader disease strategies.
A personnel appointment is not in itself a clinical breakthrough, but it often reveals that an emerging drug developer is preparing to cross its next threshold: moving from a scientific concept toward more rigorous capital, clinical, and commercial validation.
A direct comparison of rituximab and ocrelizumab brings a long-standing question in clinical practice to the surface: if efficacy is similar, should an expensive standard drug still be the only answer?
Divarasib is directly challenging existing KRAS G12C drugs in a late-stage trial. If the full data and regulatory review hold up, targeted therapy for lung cancer could see the first new option to establish superiority through a true same-class comparator.
A Norwegian and Swedish clinical trial shows that rituximab’s efficacy and safety in newly diagnosed relapsing multiple sclerosis may be no worse than those of the more expensive ocrelizumab; this is not only a question of drug choice, but also affects whether early high-efficacy treatment can become affordable for more people.
Anthropic’s new platform is making a real bet not just on having models propose candidate molecules, but on bringing data, code, structural biology tools, and decision records onto the same lab bench. That also shifts the bottleneck in AI drug development from “whether it can generate answers” to “whether it can leave behind verifiable evidence.”
Outbreaks in the Democratic Republic of the Congo and Uganda have turned a virus strain long lacking commercial incentives into an urgent vaccine R&D priority; three technology approaches are starting at the same time, and the real test is whether speed, evidence, and manufacturing capacity can align amid uncertainty.